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KAJIAN AKTIVITI KARDIOVASKULAR EKSTRAK 
GYNURA PROCUMBENS MERR.  
DAN FRAKSINYA 
 
ABSTRAK 
 
Gynura procumbens Merr. merupakan herba malar hijau yang digunakan secara 
tradisional untuk rawatan demam, ruam, penyakit buah pinggang, kencing manis 
dan hipertensi. Dalam kajian ini, kesan kardiovaskular berpandukan pengekstrakan 
dan fraksinasi G. procumbens telah dilakukan dalam usaha untuk mencari ekstrak 
aktif dan fraksi. Tumbuhan itu di keringkan, dikisar, diekstrak dengan kepekatan 
etanol : air yang berbeza (95%, 75%, 50%, 25% v/v) dan air. Ekstrak telah 
dikeringkan di bawah tekanan yang rendah dan kemudian dibeku-kering. Kesan 
ekstrak telah diperiksa pada cincin aorta tikus dan atrium kanan & kiri. Ekstrak air 
(GPWE) didapati paling aktif dalam pengenduran fenilefrin (PE) pra-kontraksi pada 
cincin aorta; kesan isoprenalina (IsoP) terhadap pengecutan maksimum dan degupan 
per minit atrium kiri dan kanan. Dengan cara pengekstrakan pelarut pelarut, larutan 
akueus GPWE difraksi menggunakan n-butanol. Kesan fraksi beku-kering kemudian 
dikaji secara ‘in vitro’ pada cincin aorta terpencil dan sediaan atrium. Antara dua 
fraksi, tiada yang mengekalkan aktiviti kardiovaskular. Penyingkiran endothelium 
pada cincin aorta menghapuskan kesan pengenduran vaskular oleh GPWE. Ekstrak 
air (GPWE) juga didapati lebih aktif menurunkan tekanan darah dan kadar denyutan 
jantung pada tikus yang dibius tetapi sama dalam kajian ‘in vitro’; fraksi GPWE 
kurang berkesan dalam menurunkan tekanan darah dan kadar denyutan jantung tikus 
yang dibius. Dos tunggal GPWE, 1 g kg-1, p.o., menghasilkan pengurangan ketara 
xxiv 
 
panjang berkekalan dalam tekanan arteri min (MAP) dan kadar denyutan jantung 
tikus sedar normotensi dan hipertensi pada 24 h. Dos yang berulang GPWE 600 mg 
kg-1, p.o., (GPWE600) mengurangkan MAP secara signifikan selepas 2 minggu, 
manakala 300 mg kg-1,p.o., (GPWE300) mengurangkan selepas 4 minggu dan 20 
mg kg-1, p.o., verapamil (Vera20) menurunkan MAP dalam minggu pertama. 
Pengurangan dalam MAP pada semua kumpulan rawatan telah disertai dengan 
kejatuhan pada kadar jantung dari minggu pertama. Pengurangan yang signifikan 
pada berat badan, peningkatan dalam pengambilan air dan pengeluaran air kencing 
pada tikus hipertensi yang dirawat dengan GPWE dan verapamil telah diperhatikan. 
Dalam masa empat minggu tikus hipertensi dibius yang dirawat (GPWE600), kesan 
pengurangan MAP asetilkolina (ACh) & IsoP dan kesan pressor metoksamin (Mtx) 
telah dikurangkan secara signifikan. Sebaliknya, tiada perubahan signifikan dalam 
MAP telah dilihat dengan PE & angiotensin II (AngII). Perubahan dalam kadar 
jantung dengan ACh, PE, Mtx, AngII dan IsoP bagi GPWE600 tikus yang telah 
dibius direncatkan oleh GPWE 600 mg kg-1 secara signifikan. Peningkatan penanda 
bio buah pinggang dan hati telah dikurangkan secara signifikan pada tikus hipertensi 
dirawat dengan GPWE dan verapamil. Selain itu tiada keabnormalan utama melalui 
pemeriksaan histopatologi telah dilihat pada tikus hipertensi yang dirawat dengan 
GPWE dan verapamil. Hasil kajian mencadangkan bahawa G. procumbens 
menghalang kesan kardiovaskular secara tidak kompetitif. Analisis kimia GPWE 
menggunakan penyaringan fitokimia dan LCMS menunjukkan kehadiran flavonoid 
dan tanin. Ekstrak tersebut juga kaya dengan ion kalium. 
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STUDY OF CARDIOVASCULAR ACTIVITIES OF 
GYNURA PROCUMBENS MERR. 
EXTRACT AND ITS FRACTIONS 
 
ABSTRACT 
 
Gynura procumbens Merr. is an evergreen herb traditionally used for treatment of 
eruptive fevers, rash, kidney disease, diabetes and hypertension. In the present study, 
the cardiovascular effects-guided extraction and fractionation of G. procumbens was 
performed in an attempt to find the active extract and fraction. The plant was dried, 
milled and extracted with different concentrations of ethanol:water (95%, 75%, 
50%, 25% v/v) and water. The extracts were dried under reduced pressure and later 
freeze-dried. The effect of the extracts was examined on isolated rat aortic ring and 
isolated right & left atrium. The water extract (GPWE) was found to be the most 
potent in relaxing phenylephrine (PE) precontracted aortic rings; isoprenaline (IsoP) 
induced maximum contractions and beats per minute for left & right atrium. By 
means of solvent-solvent extraction, the aqueous GPWE solution was fractionated 
using n-butanol. The effects of the freeze-dried fractions were then investigated in 
vitro on isolated aortic rings and atrium preparations. Among the two fractions, none 
retained the cardiovascular activity. Removal of the endothelium of the aortic ring 
completely abolished the vascular relaxing properties of GPWE also. The water 
extract (GPWE) also was found to be potent in lowering blood pressure and heart 
rate of anesthetized rats but alike ‘in vitro’ studies; the fractions of GPWE were less 
effective in lowering blood pressure and heart rate of anaesthetized rats. Single dose 
of GPWE, 1 g kg-1, p.o., produced significant long lasting reduction in mean arterial 
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pressure (MAP) and heart rate of conscious normotensive and hypertensive rats 
during 24 h. Repeated dose of GPWE 600 mg kg-1, p.o., (GPWE600) significantly 
reduced the MAP after 2 weeks, while 300 mg kg-1, p.o. (GPWE300) reduced after 4 
weeks and 20 mg kg-1, p.o., by gastric gavage of verapamil (Vera20) lowered MAP 
in first week. The reduction in MAP in all treatment groups was accompanied by 
drop in heart rate from first week. Significant reduction in weight gain, increase in 
water intake and urine output in GPWE and verapamil treated hypertensive rats was 
observed. In anaesthetized four weeks treated hypertensive rats (GPWE600), the 
MAP lowering effect of acetylcholine (ACh) & IsoP and pressor effect of 
methoxamine (Mtx) were significantly reduced. Conversely, no significant changes 
in MAP were seen with PE & angiotensin II (AngII). The change in heart rate with 
ACh, PE, Mtx, AngII and IsoP in GPWE600 anaesthetized rats was significantly 
blocked. Increased renal and hepatic biomarkers were significantly reduced in 
GPWE and verapamil treated hypertensive rats, while no major histopathological 
abnormalities were seen in GPWE and verapamil treated hypertensive rats. The 
results suggest that G. procumbens induced its cardiovascular effects non-
competitively. Chemical analysis of GPWE using phytochemical screening and 
LCMS indicated the presence of flavonoids and tannins. The extract was also found 
to be rich in potassium ions. 
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CHAPTER ONE 
INTRODUCTION 
The cardiovascular homeostasis is maintained by the balance amongst the 
volume of blood in the circulatory system, the efficiency of the heart to pump out 
blood, the regulation of arterial vascular resistance and the kidney function. The 
development of an elevated blood pressure (BP) or hypertension is presumed to be 
the consequence of inadequate functioning of any one component of this 
cardiovascular-renal control interaction. It’s been reported that hypertension is 
affecting up to 26% of the adult population of most developed nations is affected 
(Kearney et al., 2005). The long term elevated BP results in stress on whole 
cardiovascular system, in particular on arteries, arterial resistance vessels, the 
cerebrovascular circulation, the heart and the kidneys, and leads to increased risk of 
target-organ damages, such as stroke, myocardial infarction, left ventricular 
hypertrophy, heart failure and end-stage renal failure (Chobanian et al., 2003). The 
blood pressure readings above the optimal level increase the risk associated with 
higher BP and is graded and continuous throughout the distribution. The blood 
pressure in the body depends on the following interrelated factors:  
 The force of contraction of the heart -- how much the heart muscle gets 
stretched by the incoming blood.  
 The degree to which the arteries and arterioles constrict -- increases the 
resistance to blood flow, thus requiring a higher blood pressure.  
 The circulating blood volume -- the increase in the circulating blood 
volume, increases the stretching of heart muscle by the incoming blood.  
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The kidney influences blood pressure by:  
 causing the arteries and veins to constrict.  
 increasing the circulating blood volume. 
 
1.1 The Cardiovascular system 
The cardiovascular system is an organ system that transports nutrients (such 
as electrolytes, amino acids and lymph), blood cells, gases, hormones, etc. to and 
from cells in the body. This circulation helps to stabilize body temperature and pH, 
maintain homeostasis and fight diseases. This system is comprised of the heart and 
the circulatory system (blood vessels and blood). 
 
1.1.1 Heart 
1.1.1.1 Anatomy 
The heart is a myogenic muscular organ found in all animals with a 
circulatory system, which pumps blood throughout the blood vessels by repeated, 
rhythmic contractions. It is enclosed in a double-walled fibrous sac called 
pericardium. This sac protects the heart, anchors its surrounding structures, and 
prevents overfilling of the heart with blood. The wall of the heart is composed of 
three layers. The outermost layer is, epicardium, the middle layer, which contracts, 
composed of cardiac muscle is known as myocardium, the innermost layer is 
endocardium, it merges with the inner lining (endothelium) of blood vessels and 
covers heart valves.  
The heart is separated into right and left halves, each half consisting of an 
atrium and a ventricle. The two ventricles are separated by a muscular wall, the 
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interventricular septum. The atrium and ventricle, in each half of the heart are 
separated by the  
 
 
 
Figure 1.1 Diagrammatic section of the heart. 
(Adapted from McKinley and O'Loughlin, 2007) 
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atrioventricular (AV) valves, which allow blood to flow from atrium to ventricle but 
not in the reverse direction. The right AV valve has three fibrous flaps or cusp and is 
known as tricuspid valve. The left AV valve has two flaps and is therefore called the 
bicuspid valve (Figure 1.1). The openings of the right ventricle into the pulmonary 
trunk and of the left ventricle into the aorta encompass semilunar valves, owing to 
the half-moon shape of the cusps and these are the pulmonary and aortic valves 
respectively. These valves permit blood to flow into the arteries during ventricular 
contraction but prevent blood from moving back into ventricles during relaxation. 
No valves are present at the entrances of the superior and inferior venae cavae into 
the right atrium, and of the pulmonary veins into the left atrium. However, atrial 
contraction pumps very little blood back into the veins as atrial contraction 
constricts their sides of entry into the atria, significantly increasing the resistance to 
backflow (Widmaier et al., 2006). 
 
1.1.1.2 Cardiac muscle 
Cardiac muscle is a type of involuntary striated muscle found in the walls 
and histological foundation of the heart, specifically the myocardium. Cardiac 
muscle possesses properties of both skeletal and smooth muscle. The cardiac cells 
striated arrangement of thick myosin and thin actin filaments is similar to that of 
skeletal muscle. Cardiac muscle cells (cardiac myocytes) are significantly shorter 
than skeletal muscle fibers and have several branching processes. Adjacent cells are 
joined end to end at structures known as intercalated disks, within which the 
desmosomes are located. The later hold the muscle cells together and to which the 
myofibrils are attached. Adjacent to the intercalated disks, there are gap junctions, 
like those in many smooth muscles (Widmaier et al., 2006).  Cardiac muscle is 
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highly resistant to fatigue due to the presence of a large number of mitochondria, 
myoglobin and a good blood supply allowing continuous aerobic metabolism 
(Ganong, 2005). 
 
1.1.1.3 Cardiac cycle 
The cardiac contraction involves cyclic events, so called cardiac cycle. There 
are two phases of the cardiac cycle, diastole phase, the heart ventricles are relaxed 
and the heart fills with blood and systole phase, the ventricles contract and pump 
blood into the arteries. The frequency of the cardiac cycle is described by the heart 
rate.  
The right and left atria contract simultaneously in the cardiac cycle, the 
events that are occurring on left side of the heart are parallel to the events occurring 
on the right side of the heart. The ventricles contract shortly after the atria. The 
sinoatrial node sends out electrical waves of excitation to both atria, and it is 
prevented from travelling down into the ventricles directly by strands of non-
conducting fibrous tissue present laterally from the tricuspid/bicuspid valves to the 
septum. These waves of excitation travel towards the septum and into the 
atrioventricular (AV) node, where they are held for roughly 0.1 seconds. They are 
then discharged down the bundle of His, later down the Purkinje fibre, which are 
both situated inside the septum. The waves flow down towards the apex of the heart 
and are then discharged into the ventricles, causing them to contract (ventricular 
systole). This creates the beat of the heart (Guyton, 2006; Klabunde, 2007). 
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1.1.1.4 Physiology of cardiac muscle contraction 
Cardiac myocytes can be divided into work cells and pacemaker cells. The 
work cells have a large stable resting membrane potential and display a prolonged 
action potential with a plateau phase. The pacemaker cells have smaller unstable 
resting potentials and spontaneously depolarize, generating the intrinsic electrical 
activity of the heart. Pacemaker cells are found in the sinoatrial (SA) and 
atrioventricular (AV) nodes. The cells of the bundle of His and some Purkinje cells 
are also capable of spontaneous firing (Pinnell and Turner, 2007).  
On stimulation, myocardium membrane depolarizes, resulting in shortening 
of the contractile proteins followed by relaxation when the membrane potential 
returns to the resting state. The cells of the cardiac muscle are interconnected in 
groups that act in response to stimuli as a unit, contracting together whenever a 
single cell is stimulated (Howland and Mycek, 2006). 
 
1.1.1.4.1 Cardiac action potential 
The cells of cardiac muscle show spontaneous intrinsic rhythm produced by 
specialized “pace maker cells” located in the sinoatrial (SA), and atrioventricular 
(AV) nodes. Unlike nerve cells, the cardiac cells have long action potential which 
can be divided into five distinct phases (0-4) as shown in Figure 1.2. Phase (0): 
represents the fast depolarization, during which fast inward sodium (Na+) current to 
the cells occurs. Na+ channels close around +30 mv. Phase (1): is characterized by 
partial repolarization as result of outward potassium (K+) current. Phase (2): is called 
the plateau phase in which calcium (Ca2+) is exchanged to K+ to aid in cardiac 
contraction process. The plateau phase of the action potential lasts about 250 msec.  
Phase (3): represents the repolarization phase of the cardiac action potential, as Ca2+ 
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channels close, and K+ channels open and K+ moves out of cell. Phase (4): is the last 
phase of the action potential. It is known as forward current or spontaneous 
depolarization and is characterized by gradual increase in cellular permeability to 
Na+ (Howland and Mycek, 2006). 
 
 
 
 
Figure 1.2 The cardiac action potential wave forms in adult human. 
(Adapted from Nerbonne and Kass, 2005) 
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1.1.1.4.2 Pacemaker action potential 
The pacemaker potential is seen in cells in the SA and AV nodes. As shown 
in Figure 1.3, it differs from the action potential of cardiac myocytes, in that phases 
1 and 2 are absent. Pacemaker cells unstable resting action potential and the 
spontaneous depolarization of the pacemaker potential gives the heart its auto-
rhythmicity. The pacemaker potential is generated by a reduction in membrane 
permeability to K+, because of Ca2+ influx, and increased Na+ current because of 
Na+- Ca2+ exchange. Once the threshold potential is reached, Ca2+ enters the cell, 
and depolarization occurs. In contrast to the cardiac myocyte action potential, there 
is no inward movement of Na+ during depolarization. Repolarization (phase 3 of the 
action potential) occurs because of an increase in K+ permeability. At the SA node, 
K+ permeability can be further enhanced by vagal stimulation. This has the effect of 
hyperpolarizing the cell and reducing the rate of firing. Sympathetic stimulation has 
the opposite effect. 
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Figure 1.3 The pacemaker action potential waveforms.  
 
1.1.1.4.3 Cardiac contraction 
The contractile property of the myocardial cell is fundamentally similar to 
that of striated muscle. As action potential moves across cell membrane, and down 
T-tubules the voltage-gated Ca2+ channels open on cell surface. Ca2+ activates Ca2+ 
channels on endoplasmic reticulum. Ca2+ floods into the cytosol (contributes to 
plateau phase described above, as well as to prolonged contraction of cardiac muscle 
about 3 times longer than skeletal muscle contraction). Ca2+ binds to troponin, and 
tropomyosin then moves away from binding sites on actin, allowing cross bridge 
cycling just as in skeletal muscle. Ca2+ is eventually removed by active transport, 
and muscle relaxes. The contraction force of the cardiac muscle is directly 
proportional to the concentration of free cytosolic Ca2+.  Hence, agents that increase 
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Ca2+ levels (or increase the sensitivity of the contractile machinery) bring about an 
increase in the force of contraction (inotropic effect) (Howland and Mycek, 2006).  
 
1.1.2 Systemic and pulmonary circulation  
As reported by British physiologist, William Harvey in 1628, the 
cardiovascular system is formed of two, closed circuit of vessels. The blood is 
pumped out of the heart through one set of vessels and returns to the heart by 
another set. These two circulatory circuits (Figure 1.4) originate and terminate in the 
heart. The heart is also divided longitudinally into two functional halves, each 
containing two chambers: an upper chamber, the atrium, and a lower chamber, the 
ventricle. The atrium of each side pumps blood into the ventricle on that side. No 
direct flow between the two atria or the two ventricles in adult heart is found 
(Widmaier et al., 2006). 
In thirteenth century, Ibn Al-Nafis, an eminent Arab physician, defined the 
pulmonary circulation. Based on his report, the blood pumped from the right 
ventricle pass through lungs and returns to the left atrium is the pulmonary 
circulation. While the blood pumped from the left ventricle, run through all the 
organs and tissues of the body except the lungs, and returns to the right atrium, is 
systemic circulation. The vessels carrying blood away from the heart are called 
arteries, and those bringing back blood from body organs and tissues to the heart are 
called veins (Al-Ghazal, 2007). 
 In the systemic circuit, blood leaves the left ventricle by a single artery, the 
aorta (Figure 1.4). From the aorta, the arteries of the systemic circulation branch off, 
dividing into smaller vessels, the smallest arteries branch into arterioles, which in 
turn branch into a large number (estimated at 10 billion) of exceedingly small 
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vessels called capillaries, which fuse to form larger-diameter vessels, the venules. 
The arterioles, capillaries, and venules together comprise the microcirculation. The 
venules in the systemic circulation join to form larger vessels, the veins. Two large 
veins formed, the inferior vena cava which accumulates blood from organs and 
tissues below the heart, and the superior vena cava collects blood from organs and 
tissues above the heart. These two main veins return the blood to the right atrium.  
In pulmonary circulation, blood leaves the right ventricle through a single 
large artery known as the pulmonary trunk. This large artery divides into two 
pulmonary arteries, supplying the right and left lung. In the lungs, the arteries 
continue to divide, eventually forming capillaries that join into venules and then 
veins. Four pulmonary veins carry the blood from lungs and empty into the left 
atrium.  
While blood circulates through the lung capillaries, it exchange carbon 
dioxide with oxygen supplied to the lungs through breathing process. Therefore, 
high oxygen contents are found in the blood in the pulmonary veins, left side of the 
heart, and systemic arteries. After this oxygenated blood circulates through 
peripheral tissues and organs capillaries, some of this oxygen is exchanged with 
carbon dioxide from the blood, resulting in the lower oxygen content of blood in the 
venous side of the systemic circulation. 
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Figure 1.4 The systemic and pulmonary circulation. 
(Adapted from McKinley and O'Loughlin, 2007) 
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1.1.2.1 Arteries and arterioles 
One of the root causes responsible for the essential hypertension is the 
increase of peripheral resistance to the flow of blood in circulatory system. Small 
arteries (with a diameter less than 300µm) and the arterioles, constituting the distal 
part of arterial vasculature (the resistance vessels), mainly contribute in 
determination of peripheral resistance (Christensen and Mulvany, 2001). The wall of 
an artery comprises of three distinct layers namely tunica intima, tunica media and 
tunica adventitia (Figure 1.5). Tunica intima, the inner most layer of the artery wall, 
consists of a single layer of longitudinally arranged endothelial cells, and is 
separated from the circumferentially-arranged smooth muscle cells and connective 
tissue of the tunica media by an internal elastic lamina (Ganong, 1999). The 
outermost, tunica adventitia consists of collagen, fibroblasts and sympathetic nerves. 
It is the lumen diameter, which determines the resistance caused by the arteries.  
The aorta and other systemic arteries are low-resistance conducting tubes. 
Due to presence of large amount of elastic tissues in vessel walls, they act as a 
“pressure reservoir” for blood flow through the tissues during diastole (Widmaier et 
al., 2006).  
They are stretched during systole and recoil during diastole. The arteriole 
walls have less elastic tissue but much more smooth muscle. The muscle is 
innervated by noradrenergic nerve fibers, which are constrictor in their function and 
in some cases by cholinergic fibers (e.g., coronary vessels), which act by dilating the 
vessels. The arterioles are the main site of the resistance to blood flow, and little 
changes in their diameter result in large changes in the total peripheral resistance 
(TPR) (Ganong, 1999). 
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Figure 1.5 Diagrammatic section of the blood vessel. 
(Adapted from Guyton, 1991a) 
 
 
 
 
 
 
media 
intima 
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1.1.2.1.1 Contraction of vascular smooth muscle  
The vascular smooth muscle (VSM) undergoes slow, persistent and tonic 
contractions. Vascular smooth muscle, actin and myosin filament are appropriately 
organized for maintaining tonic contractions and reducing lumen diameter. 
Contraction results with the filaments slide over on one another. This movement is 
facilitated by the process of cross-bridge cycling. Contraction in vascular smooth 
muscle can be triggered by mechanical, electrical, and chemical stimuli. Contraction 
can result from the passive stretching of vascular smooth muscle and is known as 
myogenic response. Electrical depolarization of the vascular smooth muscle cell 
membrane also stimulates contraction, probably by opening voltage dependent 
calcium channels (L-type calcium channels), which causes an increase in the 
intracellular concentration of calcium.  Finally, a number of chemical stimuli such as 
norepinephrine, angiotensin II, vasopressin, endothelin-1, and thromboxane A2 can 
cause contraction. These substances bind to specific receptors on the vascular 
smooth muscle cell (or to receptors on the endothelium adjacent to the VSM), 
resulting in vascular smooth muscle contraction.   
All the mechanisms of contraction involves different signal transduction 
pathways, however result in increased intracellular calcium, which is the primary 
signal for smooth muscle contraction (Bolton, 1979; Karaki and Weiss, 1984). In 
resting smooth muscle, increase in Ca2+ concentration from 80 to 270 mM to 500 
mM to 700 mM results in contraction (Webb, 2003). The mechanism by which an 
increase in intracellular calcium stimulates vascular smooth muscle contraction is 
explained in the Figure 1.6.  An increase of free intracellular calcium results, either 
with increased influx of calcium through calcium channels or by discharge of 
calcium from internal stores (sarcoplasmic reticulum). The free calcium binds with 
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the special calcium binding protein called calmodulin.  Calcium-calmodulin 
activates myosin light chain kinase (MLCK), an enzyme that results in 
phosphorylation of myosin light chains (MLC) in the presence of ATP.  Myosin 
light chains are 20-kD regulatory subunits found on the myosin heads. 
Phosphorylated MLC cause formation of cross-bridge between the myosin heads 
and the actin filaments, and hence, smooth muscle contraction. Intracellular calcium 
concentrations, therefore, are very important in regulating smooth muscle 
contraction.  The concentration of intracellular calcium depends upon the balance 
between the calcium that enters the cells, the calcium that is discharged by 
intracellular storage sites and moving of calcium either back into storage sites or out 
of the cell. Calcium is restored in the sarcoplasmic reticulum by an ATP-dependent 
calcium pump. Calcium is removed from the cell to the external environment by 
either an ATP-dependent calcium pump or by the sodium-calcium exchanger. 
The contractile force, however, does not depend directly on intracellular 
Ca2+, as the contractile force can be enhanced by increasing the responsiveness of 
the contractile machinery or the sensitivity of the myofilaments to intracellular Ca2+ 
(Webb, 2003). These modulatory mechanisms for changing the Ca2+ metabolism, 
serve an important role in the regulation of vascular smooth muscle tone (Somlyo et 
al., 1999; Webb, 2003).  
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Figure 1.6 Mechanisms of contraction of vascular smooth muscle cells. 
(Adapted from Klabunde, 2011) 
 
Abbreviations 
SR - sarcoplasmic reticulum, Ca2+ - calcium ion, cAMP - cyclic adenosine 
monophosphate, ATP - adenosine triphosphate, MLC – myosin light chain, MLCK – 
myosin light chain kinase. 
 
 
1.1.2.1.2 Relaxation of vascular smooth muscle  
Relaxation of vascular smooth muscle involves drop in intracellular Ca2+ 
levels to resting levels and dephosphorylation of myosin light chain. Vascular 
smooth muscle relaxation follows either removal of the contractile stimulus or by 
direct inhibition of the contractile mechanism. This process is catalyzed by a 
specific enzyme myosin light chain phosphatase (MLCP) (Somlyo et al., 1999). 
Changes leading to reduction in intracellular Ca2+ levels and/or increase in MLCP 
activity add to alterations in responsiveness of smooth muscle cells. Several 
mechanisms have been implicated in the removal of cytosolic Ca2+. The inhibition of 
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sarcoplasmic reticular Ca2+ /Mg2+- ATPase activity facilitates the translocation of 
intracellular Ca2+ to sarcoplasmic reticulum, result in reduction in cytosolic Ca2+ 
concentrations and hence causes relaxation of smooth muscle cells (Webb, 2003). 
Furthermore, the inhibition of receptor-operated and voltage-operated Ca2+ channels 
in the plasma membrane, which help the Ca2+ influx and smooth muscle contraction, 
leads to the reduction in intracellular Ca2+ concentrations and hence causes smooth 
muscle relaxation (Webb, 2003). 
 
1.1.2.2 Endothelium  
Until recently, it was thought that the vascular endothelial cells simply acted 
as an inert barrier between the vessel wall and lumen. Recent studies have shown, 
the endothelium is a dynamic endocrine organ which lines the entire vascular 
system. The endothelium controls vascular function by responding to various 
hormones, neurotransmitters and vasoactive factors (Galley and Webster, 2004). The 
balanced formation of these vasoactive factors is atheroprotective, whereas 
imbalance of these factors leads to endothelial dysfunction (ED), which is an early 
indicator of atherosclerosis (Lerman and Zeiher, 2005). Endothelial cells are present 
at the interior surface of all vessels, with different structures and phenotypes in 
different vessel (Ghitescu and Robert, 2002). Endothelial cells in arteries and veins 
are continuous and thicker, while in capillaries are fenestrated and thinner to allow 
for exchange of metabolites and gases (Rhodin, 1980). In addition, endothelial cells 
can display heterogeneous responses to stimulation in different vascular beds, and 
even in different sections of the same vascular bed (Ferrer et al., 1995; Thorin et al., 
1997; Hill et al., 2001). This suggests that ED may occur in selective vascular beds 
too (Hill et al., 2001). 
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The endothelium releases various vasoactive substances, which can be 
vasodilating such as nitric oxide (NO), prostacyclin (PGI2) and endothelium derived 
hyperpolarizing factor (EDHF) or vasoconstrictive such as thromboxane (TXA2) and 
endothelin-1 (ET-1). These endothelium-derived vasoactive substances alter the 
vascular tone through local hormones, chemical substances or myogenic 
mechanisms.  
Furchgott and Zawadzki were the first to identify nitric oxide (NO), an 
endothelium-dependent vasodilator of the underlying smooth muscle (Furchgott and 
Zawadzki, 1980). Nitric oxide plays an important role in the maintenance of basal 
vasodilator tone of the blood vessels (Vallance et al., 1989). NO is formed from the 
amino acid L-arginine under the influence of the enzyme nitric oxide synthase 
(NOS) (Palmer et al., 1988). There are three isoforms of NOS: neuronal nitric oxide 
synthase (nNOS) which produces NO to regulate release of synaptic 
neurotransmitter (Prast and Philippu, 2001), macrophage or inducible isoform 
(iNOS) which is only expressed in cells that have been exposed to inflammatory 
mediators or other injurious stimuli that activate the macrophages (Michel and 
Feron, 1997), and endothelial NOS (eNOS) which produces nitric oxide in the 
vasculature (Lamas et al., 1992). Considering that the ability of a blood vessel to 
dilate is largely dependent upon the activity of eNOS, the present discussion will 
focus on this isoform. 
Endothelial nitric oxide synthase (eNOS) is located in small invaginations of 
the cell membrane (caveolae) as an inactive eNOS bound to the protein caveolin 
(Bucci et al., 2000). Increase of intracellular Ca2+ levels, separates eNOS from 
caveolin and is activated (Bucci et al., 2000). NO agonists by acting on calcium 
channel release Ca2+ from the endoplasmic reticulum or influx of calcium can 
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influence the detachment of eNOS from caveolin (Hutcheson and Griffith, 1997; 
Berkels et al., 1999; Bae et al., 2003). Examples of such NO agonists include 
bradykinin (BK), acetylcholine (ACh), adenosine triphosphate (ATP), adenosine di-
phosphate (ADP), substance P and thrombin (Moncada and Higgs, 2006). On 
depletion of intracellular Ca2+ stores an unknown signal is sent to the membrane 
receptors to open Ca2+ channels inflow of extracellular Ca2+ in the cell (Lambert et 
al., 1986; Schilling et al., 1992; Schilling and Elliott, 1992). Ca2+ attaches to the 
protein cytoplasmic calmodulin, which undergoes structural changes and activate 
eNOS (Fleming and Busse, 1999). eNOS then converts L-arginine into NO (Palmer 
et al., 1988). This mechanism of NO production works at higher levels of intra- or 
extracellular Ca2+. A reduction in Ca2+ causes the calcium calmodulin complex to 
dissociate from eNOS, which in turn binds with caveolin and becomes inactivated 
(Fleming and Busse, 1999). 
Another mechanism of eNOS activation is the phosphorylation of eNOS 
(Butt et al., 2000). Phosphorylation of eNOS occurs via protein kinases (Michel and 
Feron, 1997), such as protein kinase A (Bae et al., 2003) and cyclic guanosine-3’, 5-
monophosphate (cGMP) protein kinase dependent II (Butt et al., 2000). Shear stress 
initiates eNOS phosphorylation by the actions of protein kinase B (Akt) (Boo et al., 
2002). 
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Figure 1.7 Production of nitric oxide (NO) by endothelial cells resulting in vascular 
smooth muscle cell relaxation. 
(Adapted from Davignon and Ganz, 2004) 
 
Abbreviations 
NADPH - nicotinamide adenine dinucleotide phosphate, Ca++ - calcium ions, BH4 - 
tetrahydrobiopterin, CaM - calmodulin, eNOS – endothelial nitric oxide synthase , 
NO – nitric oxide , GTP – guanosine triphosphate, cGMP - cyclic guanosine-3’, 5-
monophosphate, sGC – soluble guanylyl cyclase  
 
 
 
Increased blood flow results shear stress in the vessel and increase NO 
production by eNOS phosphorylation and by increase of intracellular Ca2+ as a result 
of stimulation of endothelial cell receptors (Traub and Berk, 1998; Tran et al., 2000; 
Boo et al., 2002). The Ca2+ and eNOS phosphorylation induced NO production is 
dependent on the duration of the shear stress. During shorter duration of shear stress, 
s 
 22 
  
intracellular Ca2+ release (Kuchan and Frangos, 1994), while shear stress of longer 
duration (>30 min) NO production is dependent on eNOS phosphorylation (Pittner 
et al., 2005). 
Synthesized NO diffuses across the endothelial cell into the adjacent smooth 
muscle (Ignarro et al., 1986) (Figure 1.7), where it binds and activates the enzyme 
soluble guanylyl cyclase (sGC) (Ignarro et al., 1986). The activated enzyme 
increases the conversion rate of guanosine triphosphate (GTP) to cGMP (Arnold et 
al., 1977), which decreases smooth muscle tension (Jones et al., 1999). Further, 
cGMP reduces Ca2+ release from the sarcoplasmic reticulum in the smooth muscle 
cell (Collins et al., 1986), and also helps to restore Ca2+ to the sarcoplasmic 
reticulum (Cornwell et al., 1991). Both actions reduce the contraction of smooth 
muscle cells. 
Continuous active production of NO maintains the basal vasodilator tone 
(Gladwin et al., 2004). The vessels constriction resulting with NO inhibitor, NG 
monomethyl-L-arginine (L-NMMA), gave a dose dependent increase in blood 
pressure (Rees et al., 1989; Shesely et al., 1996). Administration of NO reversed the 
constriction (Rees et al., 1989; Fagan et al., 1999). However, the vessel is capable of 
dilating in the absence of NO. After removal of or damage to the endothelium, 
administration of glyceryl trinitrate (GTN) can still result in vasodilation (Vallance 
et al., 1989). The mechanism by which GTN causes vasodilation is not clear. 
Several researchers have suggested that GTN undergoes bioconversion to NO 
(Ignarro et al., 1988; Feelisch et al., 1988; Vallance et al., 1989; Marks et al., 1991), 
but not all agree, as GTN has been found to cause vasodilation without increasing 
NO (Kearney et al., 1998; Hussain et al., 1999; Artz et al., 2002; Kleschyov et al., 
2003; Nunez et al., 2005). Further, the breakdown products of GTN have been 
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shown to activate sGC (Fung et al., 1992; Tian et al.,2001). It is worth noting that 
other vasoactive agents such as calcium ionophore A23187 and isosorbide-dinitrate 
induce vasorelaxation without an increase in NO concentration (Moncada and 
Higgs, 2006). Therefore, NO does not seem to be the only agent that can activate the 
sGC-cGMP pathway. Further research is needed to identify the precise mechanism 
of the agents, in particular, more research is needed in vivo due to the differences in 
response between intact or a denuded endothelium (Galley and Webster, 2004). 
 Aside from vasodilation, NO is also involved in preventing platelet and 
leukocyte activation and adhesion to the vessel wall (Kubes et al., 1991; Nong et al., 
1997; Gidday et al., 1998; Ahluwalia et al., 2004). When the endothelium is 
damaged, the subsequent inflammation causes an increase in leukocytes at the 
damaged site (Lefer et al., 1999). Inflammatory mediators such as TNF-α, 
interleukin-1 (IL-1) and chemokines stimulate the release of iNOS (Chauhan et al., 
2003), which prevents leukocytes from adhering to the endothelium and reduces 
inflammatory mediators (Peng et al., 1998), as well as down-regulating and reducing 
the expression of adhesion molecules (Ahluwalia et al., 2004). 
 
1.1.2.2.1 Endothelial dysfunction 
Endothelial dysfunction or disruption of the normal endothelial function is 
one of the earliest steps in the progress of atherosclerosis (Drexler, 2001; 
Landmesser et al., 2004). The endothelium maintains the equilibrium between 
vasodilation and vasoconstriction, pro-thrombotic and anti-thrombotic, 
inflammatory and anti-inflammatory processes for health (Drexler, 2001; 
Landmesser et al., 2004).  For these processes production of nitric oxide (NO) is one 
of the key mediators. Balanced production of NO (vasodilator) and endothelin 
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(vasoconstrictors) maintains vascular tone. In addition to vasodilation NO reduces 
platelet adhesion, leukocyte migration and proliferation of vascular smooth muscle 
cells (Cai and Harrison, 2000; Vallance and Chan, 2001).  
Endothelial dysfunction refers to a pathological condition in which many of 
the regular functions of the endothelium are disrupted leading to a complex array of 
abnormalities including disruption of normal vaso-regulation, increased adhesion 
and migration of leukocytes, platelet aggregation and vascular smooth muscle cell 
proliferation and resulting in hypertension, atherosclerosis, platelet aggregation and 
ischemia (Landmesser et al., 2004). Reduced NO bioavailability is fundamental to 
the development of endothelial dysfunction (Cai and Harrison, 2000). The hallmark 
of endothelial dysfunction is therefore attenuated NO dependent vasodilation 
(Deanfield et al., 2007). 
During endothelium NOS activation, cofactor NADPH catalyse uncoupling 
of enzyme from caveolin and electrons donated by NADPH are transferred to 
molecular oxygen (O2) rather than L-arginine’s amine group, producing superoxide 
(O2 -) rather than NO. Thus, endothelium NOS uncoupling not only produces ROS, 
but reduces NO generation, potential for vasorelaxation (Behrendt and Ganz, 2002) 
and ROS caused modification of proteins through oxidative mechanisms are 
amplified. This results in increased oxidative stress and further increased levels of 
ROS production. 
It is been proposed that decrease in NO signaling, as result of reduced nitric 
oxide synthase (NOS) production, contribute to the endothelial dysfunction (Rees, et 
al., 1989; Moncada, et al., 1991; Caterina, 2000). Studies have shown, acetylcholine 
(ACh) mediated endothelial vasodilation and blood flow was reduced in 
